Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, multinational, open-label study of to evaluate the long-term safety, tolerability, and efficacy of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 in participants with Neurologic Manifestations of Niemann-Pick Type C1 Disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mandos LLC; Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company

Criteria

Key Inclusion Criteria:

To be eligible to participate in the study, at the Baseline Visit (except as noted below):

1. Subject completed Part B of Study VTS301 (defined as having completed Visit 27/Week 52 or completed at least through Visit 13/Week 24 and required rescue option) and is continuing in Part C of Study VTS301.

2. Subject, in the opinion of the PI, should continue treatment with VTS-270.

3. Females of childbearing potential (not surgically sterile) must use a medically acceptable method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include barrier method with spermicide, intrauterine device, steroidal contraceptive in conjunction with a barrier method, abstinence, or same-sex partner.

4. Subject or parent/guardian must provide written informed consent to participate in the study. In addition to parental consent, assent to participate must also be sought from minor children.

Key Exclusion Criteria:

A subject is ineligible for study participation if, at the Baseline Visit:

1. Subjects discontinued from Study VTS301 for AEs or perceived lack of efficacy.

2. Subject has an unresolved SAE for which treatment with VTS-270 has been halted.

3. Female subjects who are pregnant or nursing.

4. Subjects with suspected infection of the central nervous system or any systemic infection.

5. Subjects with a spinal deformity that could impact the ability to perform a LP.

6. Subjects with a skin infection in the lumbar region within 2 months of study entry.

7. Any of the following laboratory abnormalities at the Baseline Visit:

1. Neutropenia, defined as an absolute neutrophil count of less than 1.5 × 109/L.

2. Thrombocytopenia (platelet count of less than 75 × 109/L).

3. Activated partial thromboplastin time or prothrombin time prolonged by greater than 1.5 × the upper limit of normal (ULN) or known history of a bleeding disorder.

4. Aspartate aminotransferase or alanine aminotransferase (ALT) greater than 4 × ULN.

5. Anemia: hemoglobin greater than 2 standard deviations below normal for age and gender.

6. Estimated glomerular filtration rate less than 60 mL/minute/1.73 m2 calculated using the modified Schwartz formula (Schwartz et al., 2009) for subjects aged 4 through 17 years old or using the Chronic Kidney Disease Epidemiology Collaboration equation formula for subjects aged 18 years or older.

8. Evidence of obstructive hydrocephalus or normal pressure hydrocephalus.

9. Recent use of anticoagulants (in past 2 weeks prior to first dose [Study Day 0]).

10. Active pulmonary disease, oxygen requirement, or clinically significant history of decreased blood oxygen saturation, pulmonary therapy, or requiring active suction.

11. Subjects who, in the opinion of the investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.